Breast-Gynaecological & Immuno-Oncology International Cancer Conference (BGICC) Consensus and Recommendations for the Management of Triple-Negative Breast Cancer.

MedStar author(s):
Citation: Cancers. 13(9), 2021 May 08.PMID: 34066769Department: Associate Dean for Research Development | MedStar HealthForm of publication: Journal ArticleMedline article type(s): GuidelineSubject headings: IN PROCESS -- NOT YET INDEXEDYear: 2021ISSN:
  • 2072-6694
Name of journal: CancersAbstract: Background: The management of patients with triple-negative breast cancer (TNBC) is challenging with several controversies and unmet needs. During the 12th Breast-Gynaecological & Immuno-oncology International Cancer Conference (BGICC) Egypt, 2020, a panel of 35 breast cancer experts from 13 countries voted on consensus guidelines for the clinical management of TNBC. The consensus was subsequently updated based on the most recent data evolved lately. Methods: A consensus conference approach adapted from the American Society of Clinical Oncology (ASCO) was utilized. The panellists voted anonymously on each question, and a consensus was achieved when >=75% of voters selected an answer. The final consensus was later circulated to the panellists for critical revision of important intellectual content. Results and conclusion: These recommendations represent the available clinical evidence and expert opinion when evidence is scarce. The percentage of the consensus votes, levels of evidence and grades of recommendation are presented for each statement. The consensus covered all the aspects of TNBC management starting from defining TNBC to the management of metastatic disease and highlighted the rapidly evolving landscape in this field. Consensus was reached in 70% of the statements (35/50). In addition, areas of warranted research were identified to guide future prospective clinical trials.All authors: Aapro M, Abdel Aziz H, Abdel Karim K, Abulkhair O, Al-Sukhun S, Anderson BO, Aref AT, Arun B, Azim HA, Bahie Eldin N, Bakkach J, Balch CM, Conte P, El Saghir NS, El-Shinawi M, El-Zawahry HM, Elghazaly H, Elghazawy H, ElMahdy M, Foheidi M, Frolova M, Ghosn M, Giuliano AE, Gligorov J, Guarneri V, Gulluoglu BM, Kandil A, Leung JWT, Orecchia R, Paltuev RM, Penault-Llorca F, Perez EA, Poortmans P, Rugo HS, Sabry M, Shehata MA, Swain SM, Yang W, Yip CHFiscal year: FY2021Digital Object Identifier: Date added to catalog: 2021-06-28
Holdings
Item type Current library Collection Call number Status Date due Barcode
Journal Article MedStar Authors Catalog Article 34066769 Available 34066769

Background: The management of patients with triple-negative breast cancer (TNBC) is challenging with several controversies and unmet needs. During the 12th Breast-Gynaecological & Immuno-oncology International Cancer Conference (BGICC) Egypt, 2020, a panel of 35 breast cancer experts from 13 countries voted on consensus guidelines for the clinical management of TNBC. The consensus was subsequently updated based on the most recent data evolved lately. Methods: A consensus conference approach adapted from the American Society of Clinical Oncology (ASCO) was utilized. The panellists voted anonymously on each question, and a consensus was achieved when >=75% of voters selected an answer. The final consensus was later circulated to the panellists for critical revision of important intellectual content. Results and conclusion: These recommendations represent the available clinical evidence and expert opinion when evidence is scarce. The percentage of the consensus votes, levels of evidence and grades of recommendation are presented for each statement. The consensus covered all the aspects of TNBC management starting from defining TNBC to the management of metastatic disease and highlighted the rapidly evolving landscape in this field. Consensus was reached in 70% of the statements (35/50). In addition, areas of warranted research were identified to guide future prospective clinical trials.

English

Powered by Koha